Medium reagent PlentiPlex™ MYD88

for qPCRfor cancersliquid

The PlentiPlex™ MYD88 qPCR Assay combines high sensitivity with ease-of-use and is designed to work on standard real-time PCR equipment. The PlentiPlex™ MYD88 L265P assay is based on PentaBase’s novel and selective INA® technologies including the use of BaseBlockers™ that suppress false positive PCR signals from wild type templates. Open qPCR instrument procedure 0.6-0.75% MYD88 L265P LOD Results in less than 2 hours Based on INA® technology Minimal hands-on time CE IVD Product Description PCR master mix and oligonucleotide mix for quantification of MYD88 L265P mutation, positive control Format Ready-to-Use, Dispense Ready Reactions 12, 20 PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay is a semi-quantitative real-time Polymerase Chain Reaction (PCR) assay intended for in vitro diagnosis of the genomic DNA (gDNA) change giving rise to leucine to proline mutation in codon 265 (L265P) of the Myeloid differentiation primary response 88 (MYD88). Samples shall be obtained from Formalin-Fixed Paraffin-Embedded (FFPE) tissue or blood samples. The assay is used with real-time PCR systems and samples can be prepared using automated platforms or in manual workflows. The obtained results of PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay are intended for identification of the presence of the MYD88 L265P, facilitating discrimination between Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) and non-Hodgkin lymphoma.